G protein-coupled receptors (GPCRs) comprise the most important superfamily of protein targets in current ligand discovery and drug development. GPCRs are integral membrane proteins that play key roles in various cellular signaling processes. Therefore, GPCR signaling pathways are closely associated with numerous diseases, including cancer and several neurological, immunological, and hematological disorders. Computer-aided drug design (CADD) can expedite the process of GPCR drug discovery and potentially reduce the actual cost of research and development. Increasing knowledge of biological structures, as well as improvements on computer power and algorithms, have led to unprecedented use of CADD for the discovery of novel GPCR modulators. Similarly, machine learning approaches are now widely applied in various fields of drug target research. This review briefly summarizes the application of rising CADD methodologies, as well as novel machine learning techniques, in GPCR structural studies and bioligand discovery in the past few years. Recent novel computational strategies and feasible workflows are updated, and representative cases addressing challenging issues on olfactory receptors, biased agonism, and drug-induced cardiotoxic effects are highlighted to provide insights into future GPCR drug discovery.
CongreveMde GraafCSwainNATateCG.Impact of GPCR structures on drug discovery. Cell2020;
181:81–91
4.
SouthanCSharmanJLBensonHEFaccendaEPawsonAJAlexanderSPHBunemanOPDavenportAPMcGrathJCPetersJASpeddingMCatterallWAFabbroDDaviesJA.Nc-Iuphar. The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res2016;
44:D1054–D68
5.
RothBLKroezeWK.Integrated approaches for genome-wide interrogation of the druggable non-olfactory G protein-coupled receptor superfamily. J Biol Chem2015;
290:19471–7
6.
SriramKInselPA.G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?Mol Pharmacol2018;
93:251–8
7.
HauserASAttwoodMMRask-AndersenMSchiothHBGloriamDE.Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov2017;
16:829–42
8.
SantosRUrsuOGaultonABentoAPDonadiRSBologaCGKarlssonAAl-LazikaniBHerseyAOpreaTIOveringtonJP.A comprehensive map of molecular drug targets. Nat Rev Drug Discov2017;
16:19–34
9.
DozeVAPerezDM.G-protein-coupled receptors in adult neurogenesis. Pharmacol Rev2012;
64:645–75
10.
WuFSongGde GraafCStevensRC.Structure and function of peptide-binding G protein-coupled receptors. J Mol Biol2017;
429:2726–45
11.
CherezovVRosenbaumDMHansonMARasmussenSGThianFSKobilkaTSChoiHJKuhnPWeisWIKobilkaBKStevensRC.High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science2007;
318:1258–65
12.
CaffreyMLiDDukkipatiA.Membrane protein structure determination using crystallography and lipidic mesophases: recent advances and successes. Biochemistry2012;
51:6266–88
13.
MunkCIsbergVMordalskiSHarpsoeKRatajKHauserASKolbPBojarskiAJVriendGGloriamDE.GPCRdb: the G protein-coupled receptor database – an introduction. Br J Pharmacol2016;
173:2195–207
14.
KowalsmanNNivMY.GPCR & company: databases and servers for GPCRs and interacting partners. Adv Exp Med Biol2014;
796:185–204
15.
ZhaoQWuBL.Ice breaking in GPCR structural biology. Acta Pharmacol Sin2012;
33:324–34
16.
RouckJEKrapfJERoyJHuffHCDasA.Recent advances in nanodisc technology for membrane protein studies (2012-2017). FEBS Lett2017;
591:2057–88
17.
Draper-JoyceCJKhoshoueiMThalDMLiangYLNguyenATNFurnessSGBVenugopalHBaltosJAPlitzkoJMDanevRBaumeisterWMayLTWoottenDSextonPMGlukhovaAChristopoulosA.Structure of the adenosine-bound human adenosine A1 receptor-Gi complex. Nature2018;
558:559–63
18.
MaedaSQuQRobertsonMJSkiniotisGKobilkaBK.Structures of the M1 and M2 muscarinic acetylcholine receptor/G-protein complexes. Science2019;
364:552–7
19.
Garcia-NafriaJNehmeREdwardsPCTateCG.Cryo-EM structure of the serotonin 5-HT1B receptor coupled to heterotrimeric go. Nature2018;
558:620–3
20.
GaoYHuHRamachandranSEricksonJWCerioneRASkiniotisG.Structures of the rhodopsin-transducin complex: insights into G-protein activation. Mol Cell2019;
75:781–90.e3
21.
Garcia-NafriaJLeeYBaiXCarpenterBTateCG.Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein. Elife2018;
7:e35946
22.
KoehlAHuHMaedaSZhangYQuQPaggiJMLatorracaNRHilgerDDawsonRMatileHSchertlerGFXGranierSWeisWIDrorROManglikASkiniotisGKobilkaBK.Structure of the micro-opioid receptor-Gi protein complex. Nature2018;
558:547–52
23.
HauserASGloriamDEBrauner-OsborneHFosterSR.Novel approaches leading towards peptide GPCR de-orphanisation. Br J Pharmacol2020;
177:961–8
24.
GranierSKobilkaB.A new era of GPCR structural and chemical biology. Nat Chem Biol2012;
8:670–3
ZhangDGaoZGZhangKKiselevECraneSWangJPaolettaSYiCMaLZhangWHanGWLiuHCherezovVKatritchVJiangHStevensRCJacobsonKAZhaoQWuB.Two disparate ligand-binding sites in the human P2Y1 receptor. Nature2015;
520:317–21
27.
WackerDFenaltiGBrownMAKatritchVAbagyanRCherezovVStevensRC.Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc2010;
132:11443–5
28.
LeelanandaSPLindertS.Computational methods in drug discovery. Beilstein J Org Chem2016;
12:2694–718
29.
SliwoskiGKothiwaleSMeilerJLoweEWJr.Computational methods in drug discovery. Pharmacol Rev2014;
66:334–95
30.
CongreveMAndrewsSPDoreASHollensteinKHurrellELangmeadCJMasonJSNgIWTehanBZhukovAWeirMMarshallFH.Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem2012;
55:1898–903
31.
ChristopherJAAvesSJBennettKADoreASErreyJCJazayeriAMarshallFHOkrasaKSerrano-VegaMJTehanBGWigginGRCongreveM.Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). J Med Chem2015;
58:6653–64
32.
WangSWackerDLevitACheTBetzRMMcCorvyJDVenkatakrishnanAJHuangXPDrorROShoichetBKRothBL.D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science2017;
358:381–6
33.
HollingsworthSADrorRO.Molecular dynamics simulation for all. Neuron2018;
99:1129–43
34.
LeeYLazimRMacalinoSJYChoiS.Importance of protein dynamics in the structure-based drug discovery of class a G protein-coupled receptors (GPCRs). Curr Opin Struct Biol2019;
55:147–53
35.
VerdonkMLColeJCHartshornMJMurrayCWTaylorRD.Improved protein-ligand docking using GOLD. Proteins2003;
52:609–23
36.
ShermanWDayTJacobsonMPFriesnerRAFaridR.Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem2006;
49:534–53
37.
JhotiHReesSSolariR.High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?Expert Opin Drug Discov2013;
8:1449–53
38.
KoshlandDEJr.Enzyme flexibility and enzyme action. J Cell Comp Physiol1959;
54:245–58
39.
KumarSMaBTsaiCJSinhaNNussinovR.Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci2000;
9:10–9
40.
RubinMMChangeuxJP.On the nature of allosteric transitions: implications of non-exclusive ligand binding. J Mol Biol1966;
21:265–74
41.
LavecchiaADi GiovanniC.Virtual screening strategies in drug discovery: a critical review. Curr Med Chem2013;
20:2839–60
42.
KinningsSLLiuNTongePJJacksonRMXieLBournePE.A machine learning-based method to improve docking scoring functions and its application to drug repurposing. J Chem Inf Model2011;
51:408–19
43.
RodriguezDGutierrez-de-TeranH.Computational approaches for ligand discovery and design in class-A G protein-coupled receptors. Curr Pharm Des2013;
19:2216–36
44.
MartinYCKofronJLTraphagenLM.Do structurally similar molecules have similar biological activity?J Med Chem2002;
45:4350–8
45.
FaviaAD.Theoretical and computational approaches to ligand-based drug discovery. Front Biosci2011;
16:1276–90
46.
ChengJTeggeANBaldiP.Machine learning methods for protein structure prediction. IEEE Rev Biomed Eng2008;
1:41–9
47.
JabeenARanganathanS.Applications of machine learning in GPCR bioactive ligand discovery. Curr Opin Struct Biol2019;
55:66–76
48.
RosenbaumDMRasmussenSGKobilkaBK.The structure and function of G-protein-coupled receptors. Nature2009;
459:356–63
49.
MahoneyJPSunaharaRK.Mechanistic insights into GPCR-G protein interactions. Curr Opin Struct Biol2016;
41:247–54
50.
GurevichVVGurevichEV.Molecular mechanisms of GPCR signaling: a structural perspective. Int J Mol Sci2017;
18:2519
51.
WangJHuaTLiuZJ.Structural features of activated GPCR signaling complexes. Curr Opin Struct Biol2020;
63:82–9
52.
ManglikAKruseAC.Structural basis for G protein-coupled receptor activation. Biochemistry2017;
56:5628–34
53.
BurgJSIngramJRVenkatakrishnanAJJudeKMDukkipatiAFeinbergENAngeliniAWaghrayDDrorROPloeghHLGarciaKC.Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. Science2015;
347:1113–7
54.
DrorROGreenHFValantCBorhaniDWValcourtJRPanACArlowDHCanalsMLaneJRRahmaniRBaellJBSextonPMChristopoulosAShawDE.Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature2013;
503:295–9
55.
GuoDPanACDrorROMockingTLiuRHeitmanLHShawDEIjAP.Molecular basis of ligand dissociation from the adenosine A2A receptor. Mol Pharmacol2016;
89:485–91
56.
McRobbFMNegriABeumingTShermanW.Molecular dynamics techniques for modeling G protein-coupled receptors. Curr Opin Pharmacol2016;
30:69–75
57.
CiancettaASabbadinDFedericoSSpallutoGMoroS.Advances in computational techniques to study GPCR-Ligand recognition. Trends Pharmacol Sci2015;
36:878–90
58.
ChanHCSXuYTanLVogelHChengJWuDYuanS.Enhancing the signaling of GPCRs via orthosteric ions. ACS Cent Sci2020;
6:274–82
59.
YuanXRanioloSLimongelliVXuY.The molecular mechanism underlying ligand binding to the membrane-embedded site of a G-protein-coupled receptor. J Chem Theory Comput2018;
14:2761–70
SalmasoVJacobsonKA.In silico drug design for purinergic GPCRs: overview on molecular dynamics applied to adenosine and P2Y receptors. Biomolecules2020;
10:812
62.
WangJMiaoY.Mechanistic insights into specific G protein interactions with adenosine receptors. J Phys Chem B2019;
123:6462–73
63.
SchneiderG.Automating drug discovery. Nat Rev Drug Discov2018;
17:97–113
64.
PlanteAShoreDMMorraGKhelashviliGWeinsteinH.A machine learning approach for the discovery of ligand-specific functional mechanisms of GPCRs. Molecules2019;
24:2097
65.
SchonenbachNSHussainSO'MalleyMA.Structure and function of G protein-coupled receptor oligomers: implications for drug discovery. Wiley Interdiscip Rev Nanomed Nanobiotechnol2015;
7:408–27
66.
TopiolS.Current and future challenges in GPCR drug discovery. Methods Mol Biol2018;
1705:1–21
67.
LatorracaNRVenkatakrishnanAJDrorRO.GPCR dynamics: structures in motion. Chem Rev2017;
117:139–55
68.
BorodovskyABarbonCMWangYYeMPrickettLChandraDShawJDengNSachsenmeierKClarkeJDLinghuBBrownGABrownJCongreveMChengRKDoreASHurrellEShaoWWoessnerRReimerCDrewLFawellSSchullerAGMeleDA.Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103(+) dendritic cells enhancing anti-tumor immunity. J Immunother Cancer2020;
8:e000417
69.
ChristCDMarkAEvan GunsterenWF.Basic ingredients of free energy calculations: a review. J Comput Chem2010;
31:1569–82
70.
ReddyMRReddyCRRathoreRSErionMDAparoyPReddyRNReddannaP.Free energy calculations to estimate ligand-binding affinities in structure-based drug design. Curr Pharm Des2014;
20:3323–37
71.
PiresDEVVelosoWNPMyungYRodriguesCHMSilkMRezendePMSilvaFXavierJSVellosoJPLda SilveiraCHAscherDB.EasyVS: a user-friendly web-based tool for molecule library selection and structure-based virtual screening. Bioinformatics2020;
36:4200–2
72.
de VriesSJReyJSchindlerCEMZachariasMTufferyP.The pepATTRACT web server for blind, large-scale peptide-protein docking. Nucleic Acids Res2017;
45:W361–W64
73.
FenollosaCOtonMAndrioPCortesJOrozcoMGoniJR.SEABED: small molecule activity scanner weB servicE baseD. Bioinformatics2015;
31:773–5
74.
WengGWangEWangZLiuHZhuFLiDHouT.HawkDock: a web server to predict and analyze the protein-protein complex based on computational docking and MM/GBSA. Nucleic Acids Res2019;
47:W322–30
75.
LabbeCMPenchevaTJerevaDDesvillechabrolDBecotJVilloutreixBOPajevaIMitevaMA.AMMOS2: a web server for protein-ligand-water complexes refinement via molecular mechanics. Nucleic Acids Res2017;
45:W350–55
76.
LabbeCMReyJLagorceDVavrusaMBecotJSperandioOVilloutreixBOTufferyPMitevaMA.MTiOpenScreen: a web server for structure-based virtual screening. Nucleic Acids Res2015;
43:W448–54
77.
SantosKBGuedesIAKarlALMDardenneLE.Highly flexible ligand docking: benchmarking of the DockThor program on the LEADS-PEP Protein-Peptide data set. J Chem Inf Model2020;
60:667–83
78.
FiresteinS.How the olfactory system makes sense of scents. Nature2001;
413:211–8
79.
BavanSShermanBLuetjeCWAbaffyT.Discovery of novel ligands for mouse olfactory receptor MOR42-3 using an in silico screening approach and in vitro validation. PLoS One2014;
9:e92064[10.1371/journal.pone.0092064]
80.
YuanSDahounTBrugarolasMPickHFilipekSVogelH.Computational modeling of the olfactory receptor Olfr73 suggests a molecular basis for low potency of olfactory receptor-activating compounds. Commun Biol2019;
2:141
81.
WislerJWXiaoKHThomsenARBLefkowitzRJ.Recent developments in biased agonism. Curr Opin Cell Biol2014;
27:18–24
82.
WislerJWRockmanHALefkowitzRJ.Biased G protein-coupled receptor signaling changing the paradigm of drug discovery. Circulation2018;
137:2315–7
83.
BermudezMNguyenTNOmieczynskiCWolberG.Strategies for the discovery of biased GPCR ligands. Drug Discov Today2019;
24:1031–7
84.
Costa-NetoCMParreirasESLTBouvierM.A pluridimensional view of biased agonism. Mol Pharmacol2016;
90:587–95
85.
WeissDRAhnSSassanoMFKleistAZhuXStrachanRRothBLLefkowitzRJShoichetBK.Conformation guides molecular efficacy in docking screens of activated beta-2 adrenergic G protein coupled receptor. ACS Chem Biol2013;
8:1018–26
86.
BrogiSTafiADesaubryLNebigilCG.Discovery of GPCR ligands for probing signal transduction pathways. Front Pharmacol2014;
5:255
87.
MannelBJaitehMZeifmanARandakovaAMollerDHubnerHGmeinerPCarlssonJ.Structure-Guided screening for functionally selective D2 dopamine receptor ligands from a virtual chemical library. ACS Chem Biol2017;
12:2652–61
88.
McCorvyJDButlerKVKellyBRechsteinerKKarpiakJBetzRMKormosBLShoichetBKDrorROJinJRothBL.Structure-inspired design of beta-arrestin-biased ligands for aminergic GPCRs. Nat Chem Biol2018;
14:126–34
89.
PatelNHuangXPGrandnerJMJohanssonLCStauchBMcCorvyJDLiuYRothBKatritchV.Structure-based discovery of potent and selective melatonin receptor agonists. Elife2020;
9:e53779.
90.
Marti-SolanoMIglesiasAde FabritiisGSanzFBreaJLozaMIPastorMSelentJ.Detection of new biased agonists for the serotonin 5-HT2A receptor: modeling and experimental validation. Mol Pharmacol2015;
87:740–6
91.
FischerTGazzolaSRiedlR.Approaching target selectivity by de novo drug design. Expert Opin Drug Discov2019;
14:791–803
92.
SchneiderGClarkDE.Automated de novo drug design: are we nearly there yet?Angew Chem Int Ed Engl2019;
58:10792–803
BasithSCuiMMacalinoSJYParkJClavioNABKangSChoiS.Exploring G protein-coupled receptors (GPCRs) ligand space via cheminformatics approaches: impact on rational drug design. Front Pharmacol2018;
9:128
95.
DedicNJonesPGHopkinsSCLewRShaoLCampbellJESpearKLLargeTHCampbellUCHananiaTLeahyEKoblanKS.SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther2019;
371:1–14
96.
KawaiKNagataNTakahashiY.De novo design of drug-like molecules by a fragment-based molecular evolutionary approach. J Chem Inf Model2014;
54:49–56
97.
ReutlingerMRodriguesTSchneiderPSchneiderG.Multi-objective molecular de novo design by adaptive fragment prioritization. Angew Chem Int Ed Engl2014;
53:4244–8
98.
FedorovDGNagataTKitauraK.Exploring chemistry with the fragment molecular orbital method. Phys Chem Chem Phys2012;
14:7562–77
99.
ChudykEISarratLAldeghiMFedorovDGBodkinMJJamesTSoutheyMRobinsonRMoraoIHeifetzA.Exploring GPCR-Ligand interactions with the fragment molecular orbital (FMO) method. Methods Mol Biol2018;
1705:179–95
100.
HeifetzAChudykEIGleaveLAldeghiMCherezovVFedorovDGBigginPCBodkinMJ.The fragment molecular orbital method reveals new insight into the chemical nature of GPCR-ligand interactions. J Chem Inf Model2016;
56:159–72
101.
HeifetzAJamesTSoutheyMMoraoIAldeghiMSarratLFedorovDGBodkinMJTownsend-NicholsonA.Characterising GPCR-ligand interactions using a fragment molecular orbital-based approach. Curr Opin Struct Biol2019;
55:85–92
102.
ChenHEngkvistOWangYOlivecronaMBlaschkeT.The rise of deep learning in drug discovery. Drug Discov Today2018;
23:1241–50
103.
CherkasovAMuratovENFourchesDVarnekABaskinIICroninMDeardenJGramaticaPMartinYCTodeschiniRConsonniVKuz'minVECramerRBenigniRYangCRathmanJTerflothLGasteigerJRichardATropshaA.QSAR modeling: where have you been? Where are you going to?J Med Chem2014;
57:4977–5010
JaegerSFulleSTurkS.Mol2vec: unsupervised machine learning approach with chemical intuition. J Chem Inf Model2018;
58:27–35
106.
KadurinANikolenkoSKhrabrovKAliperAZhavoronkovA.druGAN: an advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties in silico. Mol Pharm2017;
14:3098–104
107.
LiuXYeKvan VlijmenHWT, AIvan WestenGJP.An exploration strategy improves the diversity of de novo ligands using deep reinforcement learning: a case for the adenosine A2A receptor. J Cheminform2019;
11:35
108.
RatajKKelemenAABreaJLozaMIBojarskiAJKeseruGM.Fingerprint-based machine learning approach to identify potent and selective 5-HT2BR ligands. Molecules2018;
23:1137
109.
CrastoCMarencoLMillerPShepherdG.Olfactory receptor database: a metadata-driven automated population from sources of gene and protein sequences. Nucleic Acids Res2002;
30:354–60
110.
BushdidCde MarchCAFiorucciSMatsunamiHGolebiowskiJ.Agonists of G-protein-coupled odorant receptors are predicted from chemical features. J Phys Chem Lett2018;
9:2235–40
111.
PriestBTBellIMGarciaML.Role of hERG potassium channel assays in drug development. Channels2008;
2:87–93
112.
RyuJYLeeMYLeeJHLeeBHOhKS.DeepHIT: a deep learning framework for prediction of hERG-induced cardiotoxicity. Bioinformatics2020;
36:3049–55
113.
VilloutreixBOTaboureauO.Computational investigations of hERG channel blockers: new insights and current predictive models. Adv Drug Deliv Rev2015;
86:72–82
114.
WangSLiYXuLLiDHouT.Recent developments in computational prediction of HERG blockage. Curr Top Med Chem2013;
13:1317–26
115.
TaboureauOJorgensenFS.In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. Comb Chem High Throughput Screen2011;
14:375–87
116.
NegamiTArakiMOkunoYTeradaT.Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs. Sci Rep2019;
9:16586.
117.
Du-CunyLChenLZhangS.A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling. J Chem Inf Model2011;
51:2948–60
118.
BragaRCAlvesVMSilvaMFMuratovEFourchesDLiaoLMTropshaAAndradeCH.Pred-hERG: a novel web-accessible computational tool for predicting cardiac toxicity. Mol Inform2015;
34:698–701
119.
ChemiGGemmaSCampianiGBrogiSButiniSBrindisiM.Computational tool for fast in silico evaluation of hERG K(+) channel affinity. Front Chem2017;
5:7
120.
ZhangYMZhaoJNWangYCFanYRZhuLYangYChenXYLuTChenYDLiuHC.Prediction of hERG K plus channel blockage using deep neural networks. Chem Biol Drug Des2019;
94:1973–85
